** Shares in French pharmaceutical company Boiron BOIR.PA
down 3% after falling as much as 13% at the resumption of
trading
** On Thursday, the shares were suspended at the company's
request after an independent scientific body that works with
French authorities and the healthcare sector (HSA) recommended
ending the reimbursement of homeopathic medicines urn:newsml:reuters.com:*:nL5N22S6SW
** A Paris-based analyst confirms the negative advice is the
main driver behind the drop in the homeopatic drugmaker's share
price
** In a worst-case scenario, the analyst estimates a
reduction of around 30% in earnings per share for the next 2 to
3 years
((bruno.dubrulle@thomsonreuters.com))